文献速递造血干细胞移植与细胞治疗

移植后环磷酰胺联合阿巴西普预防移植物抗宿主病的前瞻性临床试验

A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept.
PubMed 文献 · Blood Adv · 2025-01-01

一项前瞻性随机临床试验,纳入接受8/8相合亲缘或非亲缘供者异基因移植的血液恶性肿瘤患者,1:1随机至他克莫司联合甲氨蝶呤的标准治疗组或移植后环磷酰胺联合阿巴西普组。试验达到主要终点:1年中重度慢性GVHD在PTCy+Aba组为0%、SOC组为65.8%(P<.0001)。

要点

  • PTCy+Aba组1年中重度慢性GVHD为0%,SOC组为65.8%(P<.0001)。
  • PTCy+Aba组无治疗相关死亡,SOC组有2例。
  • GVHD无复发生存PTCy+Aba组62.5%,SOC组24.1%(P=.010)。

核心结论

  • PTCy+Aba耐受良好,并与慢性GVHD减少及GVHD无复发生存改善相关。

研究设计与样本

  • 前瞻性随机临床试验,纳入接受8/8相合亲缘或非亲缘供者异基因移植的血液恶性肿瘤患者,1:1随机至SOC组或PTCy+Aba组。
  • PTCy+Aba组25例,SOC组15例;所有患者接受外周血采集的干细胞。
  • 主要终点为1年中重度慢性GVHD。
  • 美国食品药品监督管理局批准Aba用于GVHD预防导致机构标准治疗改变后,试验修正为仅入组PTCy+Aba组。
  • 试验注册号NCT03680092。

主要发现

  • 1年中重度慢性GVHD的Kaplan-Meier估计值:PTCy+Aba组0% vs SOC组65.8%(P<.0001)。
  • GVHD无复发生存:PTCy+Aba组62.5% vs SOC组24.1%(P=.010)。
  • 治疗相关死亡:PTCy+Aba组0例 vs SOC组2例。
  • 总生存:PTCy+Aba组92% vs SOC组80%(P=.28);无病生存:PTCy+Aba组68% vs SOC组92.9%(P=.105);1年感染率两组相似。
  • 3/4级急性GVHD发生率:PTCy+Aba组4.2% vs SOC组21.4%(P=.092)。

关键数值与推荐

  • PTCy+Aba方案:移植后第+3天和第+4天给予PTCy,随后第+5天、+14天、+28天及每4周至第+168天给予Aba。
  • SOC方案:他克莫司联合甲氨蝶呤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 美国食品药品监督管理局批准Aba用于GVHD预防导致机构标准治疗改变后,试验修正为仅入组PTCy+Aba组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a prospective randomized clinical trial to investigate the combination of posttransplant cyclophosphamide (PTCy) and abatacept (Aba) for graft-versus-host disease (GVHD) prophylaxis. Patients with hematologic malignancies undergoing an allogeneic transplant from an 8/8 matched related or unrelated donor were randomized 1:1 to tacrolimus and methotrexate (standard-of-care arm [SOC]) or PTCy on days +3 and +4, followed by Aba on an extended schedule: days +5, +14, and +28, and every 4 weeks up to day +168 (PTCy+Aba). All patients received peripherally collected stem cells. The primary end point was moderate and severe chronic GVHD at 1 year. Following US Food and Drug Administration approval of Aba for GVHD prophylaxis leading to change in institutional SOC, the trial was amended to enroll only on the PTCy+Aba arm. A total of 25 patients enrolled on PTCy+Aba, and 15 on SOC. The trial met its primary end point: Kaplan-Meier estimates of moderate and severe chronic GVHD were 0% on the PTCy+Aba and 65.8% on the SOC arm (P < .0001). GVHD-free, relapse-free survival (GRFS) was 62.5% on PTCy+Aba and 24.1% on SOC (P = .010). There were no treatment-related deaths on PTCy+Aba and 2 on SOC. Overall survival (PTCy+Aba, 92%; SOC, 80%; P = .28), disease-free survival (PCTy+Aba, 68%; SOC, 92.9%; P = .105), and infection rates at 1 year were similar. Grade 3/4 acute GVHD rate was 4.2% on PTCy+Aba and 21.4% on SOC (P = .092). PTCy+Aba preserved regulatory T-cell proliferation and increased CD16+CD56dim cytotoxic natural killer cells. In conclusion, PTCy+Aba is well tolerated and associated with reduced chronic GVHD and improved GRFS. This trial was registered at www.ClinicalTrials.gov as #NCT03680092.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Koura D, Dykes K, Goodman A, et al. A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. Blood Adv. 2025. PMID: 40554429. doi:10.1182/bloodadvances.2024015094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。